BioPhoT invests €4,71 million in biomedicine, photonics, new materials, sensors, CO2, and autonomous systems to connect research and industry.

An injectable hydrogel to combat bone infections, laser-treated titanium surfaces with antibacterial properties, polarizing optics for augmented reality, underwater infrared laser communications, radiation-shielding materials, and new systems for converting carbon dioxide into valuable chemicals. These are some of the technologies emerging from Latvian laboratories in the coming months, ready to tackle what is often the most challenging phase of research itself: demonstrating their potential for practical application.
La BioPhoT platform has selected 26 research and innovation projects in the second round of funding, making available a total of 4.710.859 €Each group will receive up to €190.000 for eight months of activity. Ninety-nine proposals were submitted for selection, and were evaluated in two phases based on scientific quality and innovation potential.
Behind the distribution of funds lies a well-known problem in technology transfer: a scientifically promising discovery may be too advanced for basic research, but still too immature and risky to attract industrial capital. BioPhoT focuses its intervention precisely in this range, supporting technologies ranging from Technology Readiness Level, or TRL, 2 and 6, from the initial formulation of a concept to the demonstration of a prototype in a relevant environment.
From medicine to lasers, a deliberately heterogeneous portfolio
The distribution of the 26 projects also reveals where part of Latvian applied research is concentrated. Seven will be carried out by groups from theInstitute of Solid State Physics of the University of Latvia, five from the University of Latvia, four from the Latvian Institute of Organic Synthesis, and four from Riga Technical University. Two projects each are being implemented by the Latvian Biomedical Research and Study Centre and Riga Stradiņš University, while the Institute of Electronics and Computer Science and Ventspils University of Applied Sciences will each implement one project.
A significant portion concerns biomedicine and medical technologiesThe researchers will work, among other things, on a system to continuously evaluate the microcirculation of patients in intensive care, a device to analyze blood coagulation and ultrasound techniques to measure the condition of bones and muscles.
The portfolio also includes a platform artificial intelligence The research group will focus on early assessment of osteoporosis risk through dental computed tomography (CT) imaging. Other groups will focus on oncology and precision medicine, identifying specific tumor metabolic profiles to guide targeted therapies and developing a platform for real-time assessment of the efficacy of drugs against pancreatic cancer.
Pharmaceutical research includes a prototype cancer vaccine and a specialized library of compounds for the so-called fragment-based drug discovery, a method that starts from small molecules capable of binding to a biological target and uses them as starting points to design more complex drug candidates.
In the field of biomaterials, one of the projects will develop a injectable hydrogel for the treatment of bone infectionsAnother line combines photonics and medicine: titanium surfaces will be structured by laser to obtain antibacterial properties, with possible applications in medical devices.
Photonics and smart materials seek concrete applications
The second large technological family funded concerns photonics, optics, sensors and advanced materialsProjects include polarizing optics for augmented reality devices and an adaptive infrared laser communications system designed to operate underwater, where traditional radio communications face severe limitations.
Another group will develop a polymer sensor for ammonia, while semiconductor surface treatment techniques will be studied to improve image quality. Road safety is also included in the program through long-lasting luminescent coatings applicable to ordinary road signs.
Composite materials represent another area of experimentation. One research project aims to increase their radiation shielding capacity for applications. medical, space and defenseThe same logic runs through a significant portion of the program: not funding a single dominant technology, but building a portfolio of solutions with different potential markets and different levels of maturity.
The technology and energy find space. Among the selected projects is the electrocatalytic conversion ofcarbon dioxide in valuable chemicals, together with technologies for hydraulic gas compression and next-generation concepts for unmanned aircraft.
The result is a portfolio in which medicine, chemistry, photonics, electronics, and engineering frequently overlap. It is precisely at these intersections that BioPhoT seeks technologies transferable to industry, rather than simply producing publishable scientific results.
The decisive step is between a patent and the first real customer
Funding laboratories represents only one part of the model. BioPhoT supports the calls for proposals with activities dedicated to technology transfer, intellectual property and commercialization, trying to accustom scientific groups to dealing early on with questions that may remain secondary in academic research: who would use a technology, what problem it solves, how much it costs to bring it to an industrial level and who could finance that path.
On May 12, 2026, at the House of Science of the University of Latvia in Riga, more than twenty BioPhoT projects have directly addressed this step during theInnovation Impact Forum 2026The teams presented their technologies to investors, industry representatives, and innovation experts, receiving assessments on commercial maturity, market potential, and next development steps.
Among the awarded projects are: SwyCard, led by Kristaps Kļaviņš at Riga Technical University. The system studies the possibility of determining and monitoring clinically significant biomarkers through sweat analysis. In the biomedical category, it was also recognized BioCore, coordinated by Dagnija Loča, dedicated to biomaterials for infection control and rapid bone regeneration.
In the field of photonics and advanced materials, a project by Daugavpils University dedicated to smart inks for chromogenic windows, materials capable of modifying their optical properties in response to certain stimuli.
Discussions with investors and industry serve to subject technologies to criteria other than those of a scientific publication. A solution may work in the lab but require expensive materials, processes that are difficult to industrialize, lengthy certification procedures, or an insufficient market. Commercialization therefore requires simultaneous verification. technical performance, intellectual property, production, regulation and demand.
The person responsible for the platform, Osvalds Pugovičs, described this function when presenting the results of the first year of activity in February 2026:
“BioPhoT has done a lot to help the scientific community make their results visible to the commercial sector.”
Furthermore, the program is not limited to the nine organizations that make up the consortium. Groups from other Latvian universities also participated in the second round, broadening the institutional and geographical distribution of proposals.
By 2032, at least 35 technologies will have to advance in level
The scale of the program emerges better by looking beyond the individual call. In the first two competitions, a total of 223 research and innovation proposalsThe first round funded 40 projects for approximately eight million euros; with the 26 selected in the second round, the supported portfolio has further grown, while a third call has been scheduled for August 2026.
BioPhoT is part of the national research program Innovation Fund – Long-Term Research Program, funded by the Latvian Ministry of Economy and coordinated by the Latvian Institute of Organic Synthesis. The consortium includes institutions from biomedicine, chemistry, electronics, photonics, materials, food science, and engineering.
The declared goal for the 2032 is the creation of at least 35 new technologies with high commercialization potentialTwenty-three are expected to reach TRL levels 5-6, i.e., sufficient maturity to be validated or demonstrated under relevant conditions, while at least four products are expected to reach the commercialization stage.
This objective also allows the program to be measured using more stringent criteria than the simple number of funded projects. Moving from low TRLs to levels approaching industrial demonstration requires prototyping, testing, design iterations, intellectual property protection, and often new capital. Not all 26 selected projects will necessarily become products, and public funding does not eliminate technological or commercial risk.
Latvia, however, is trying to intervene precisely at the point where that risk tends to block the path. The BioPhoT model combines research and development, competitive selection, training of researchers and discussions with investors and companies, rather than waiting for the transfer to the market to occur spontaneously.
From Latvian laboratories to the international showcase of deep tech
A first international verification came in June 2026 atHello Tomorrow Global Summit in Amsterdam, where for the first time the Latvian deep tech ecosystem presented itself with a joint national delegation organized by LIAA, BioPhoT and the Riga Investment and Tourism Agency. Among the technologies displayed were SwyCard, the optical system FLARE to evaluate the response of bacteria to antibiotics through laser imaging and DURBIS, a biomimetic drone with dual helical propulsion designed to move through water, pipes and granular environments.
The distance between these prototypes and a purchasable product varies from case to case. It is precisely this distance, rather than the number of ideas born in the labs, that will determine the outcome of the Latvian experiment: by 2032, BioPhoT will have to demonstrate how many of the supported projects have successfully passed the validation, industrialization, and investment stages necessary to transform a scientifically promising technology into something a company can actually produce and a customer can use.
Here are three insights that might interest you:
Schwyz entrusts the transfer of AI and robotics to CSEM
Latvia, the unexpected outsider of innovation on the Baltic shores
High-power optical vortices: Tampere's challenge













